Aharon Schwartz - 29 Sep 2023 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role
Director
Signature
/s/ Eyal Rubin, Attorney-in-Fact
Issuer symbol
PLX
Transactions as of
29 Sep 2023
Net transactions value
$0
Form type
4
Filing time
03 Oct 2023, 17:00:32 UTC
Previous filing
05 Jan 2023
Next filing
12 Aug 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLX Stock Option (Right to Buy) Award $0 +61,676 $0.000000 61,676 29 Sep 2023 Common Stock 61,676 $1.66 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
F2 Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.